• Welcome!
    Welcome!
    Welcome!
    You can trust Epoch Heath to offer the treatment
    and support you need to achieve total wellness.
  • Expert Skill
    Epoch Health

    We are committed to providing the highest level of care for our patients.
    No one understands men’s health like we do.

  • Epoch Video Links
    Epoch Video Links

Locations and Hours

  • ANCHORAGE, AK (M-F, 8am-6pm)
    907-202-8282
  • BENTON, AR (Tu-Fri, 8am-6pm)
    1-877-321-8452
  • COLUMBIA, MO (M-F, 8am-6pm)
    573-818-3067
  • CONWAY, AR (M-W-Thu 8am-6pm)
    501-358-6062​
  • LITTLE ROCK, AR (M-F, 8am-6pm)
    501-246-3423
  • N.LITTLE ROCK, AR (M-F, 8am-6pm)
    501-945-0680​
  • TUCSON, AZ (M-F, 8am-6pm)
    520-448-0401
Find a Location Near You

Men's Healthcare. Evolved

Epoch is the next evolution in comprehensive healthcare designed for men. We match your symptoms to appropriate medical treatments, regular screenings and lifestyle modifications that return you to a healthier, happier way of life.

Learn More
 

Request an Appointment

To schedule an appointment at Epoch Men's Health, call the location nearest you, or click the button below to schedule your appointment online.

Submit Appointment Request Now

Patient Care Pathways

Latest News

6

July 2016

What Steps Can You Take to Prevent Cancer?

By: Epoch

 

June is Men's Health Month. Unfortunately, there are many cancers and diseases that men are at greater risk for than women. Sometimes men assume Family gardeningbecause of genetics that cancer is inevitable. While family history does play a role, there are definitely steps you can take to be more proactive about preventing cancer. Making some specific healthy lifestyle choices can affect your risk.

Overall, having a healthy and balanced diet will lower your risk for most cancers. Avoid too many fatty foods. One of the easiest steps is to increase the amounts of fruits and vegetables you eat. They are full of vitamins and nutrients, which are shown to decrease your cancer risk. Actually, specifically eating tomatoes and other red foods may lower your risk. Tomatoes, watermelon and other red foods get their vibrant red color from lycopene. Research has shown that men who consume these have a lower risk for prostate cancer. Cooking tomatoes can also make it easier for your body to absorb lycopene.

Try eating more fish. Omega-3, which is a type of fatty acid found in salmon, tuna and herring, can lower your risk.

Many changes will not only help lower your risk for prostate cancer but help you live a healthier life. Quitting smoking is an obvious step if you are a smoker. Incorporating exercise into your routine several days a week can also help. This can be as simple as taking a walk around your neighborhood.

Obesity also affects your cancer risk. If your body mass index (BMI) is 30 or higher, you have a greater chance of developing prostate cancer. Many of these tips will also help you shed a few pounds in the process.

If you would like to schedule a cancer screening or talk to a physician, call us today at 1-877-321-8452.

 

READ MORE

6

July 2016

From WSJ: New Prostate Cancer Tests

By: Epoch

 

 

A Better Prostate-Cancer Test?

 

By Melinda Beck

 

When Al Piazza learned he had prostate cancer, his first thought was, “Let’s get this out and be done with it,” he says. But his urologist, Jeremy Lieb, said the side effects of treatment could be more harmful than the cancer itself.

Dr. Lieb ran a genetic test on the patient’s biopsy sample, which calculated that Mr. Piazza, then 70 years old, had only a 3% chance of dying from prostate cancer over the next 10 years if he left the tumor untreated.

Four years later, the retired AT&T manager from Discovery Bay, Calif., has been monitoring his cancer with regular blood tests and imaging scans and says he is comfortable leaving it alone. “My feeling is—it’s there, but it’s not going to kill me,” Mr. Piazza says.

Al Piazza learned he doesn’t require treatment for prostate cancer after a genetic test performed on his biopsy sample revealed small odds of harm if the tumor was left untreated. 

The procedure done on Mr. Piazza’s tumor sample, called Prolaris by Myriad Genetics, is one of several new prostate-cancer tests that aim to reduce detection and treatment of tumors that are likely to be harmless while still spotting those that are lethal.

That has been a daunting challenge in recent years. Routine screenings for prostate cancer, using blood tests for prostate-specific antigen, or PSA, have dramatically increased early detection of the disease. More than 99% of cases are curable today. Most of the cancers that prostate screenings find are so slow-growing they are effectively harmless, experts say. Still, because some cancers are aggressive and deadly, most men have opted for treatment with surgery or radiation despite a significant risk of incontinence or impotence.

The ratio of potential benefit to harm is so small that the U.S. Preventive Services Task Force recommended in 2012 that men not be screened for prostate cancer at all.

 

Should I Get a PSA Test?

Many experts recommend against routine PSA blood screening for prostate cancer, leaving many men to wonder whether they should get one.

The new tests, using blood, urine and tissue samples, go well beyond PSA tests and aim to tell men, in advance, not simply if they have prostate cancer, but also if it is aggressive enough to warrant locating and treating or if it can be safely monitored instead. (Gleason scores, which pathologists use to grade prostate cancers found on biopsies, help classify them as low, intermediate or high risk but don’t always reflect the cancer’s true aggressiveness.)

“The solution isn’t to stop screening. The better idea is to use more specific tests,” says Stacy Loeb, an assistant professor of urology and population health at New York University School of Medicine, who led a session on the new tests at the American Urological Association’s annual meeting, May 6 to May 10.

Dr. Stacy Loeb, a New York University urologist, led a session on new prostate-cancer tests at the American Urological annual meeting this month.

The new tests, however, don’t provide useful information for every patient and add significantly to the cost, Dr. Loeb and other urologists caution. Few of them have been vetted by the Food and Drug Administration. And while most have been validated in retrospective studies, there’s little data on how they compare with each other or whether they will improve prostate-cancer care long term.

“It’s very exciting to have these tests available, but it’s sort of the wild west now,” says Scott Eggener, a University of Chicago urologist and a spokesman for the American Urological Association.

 

Do you need a biopsy?

Several of the new tests aim to reduce the number of needless prostate biopsies. More than 1 million U.S. men undergo the painful, intrusive procedure each year mainly because of an elevated PSA level. Overall, fewer than 20% of biopsies find prostate cancer.

The 4Kscore, developed at Memorial Sloan Kettering Cancer Center in New York, analyzes four different types of PSA-related proteins in blood samples and calculates the likelihood, from 1% to 100%, that a biopsy would find an aggressive cancer, defined as a Gleason score of 7 or above.

“It’s frightening for a patient to be diagnosed with cancer that doesn’t need to be treated. If it’s not going to bother him, then why find it?” says Peter Scardino, chairman of surgery at Memorial Sloan Kettering who advises the test’s maker, OPKO Health Inc., and is eligible for stock options. The 4Kscore became available in 2014 and costs about $1,000.

Another PSA-based test, Prostate Health Index, or PHI, from Beckman Coulter Inc., costs only about $100. It calculates the likelihood that a biopsy will find cancer but not how aggressive the cancer might be.

Other new tests check urine samples for gene fragments of prostate cancer to assess whether it is likely to be high-risk. SelectMDx, available from MDxHealth in the U.S. since April, requires a digital rectal exam first.

A new test from Exosome Diagnostics, expected to be available in June, checks for the presence of exosomes, the chemical messengers that can pave the way for cancer’s spread. A study in JAMA Oncology in March found the Exosome test correctly identified 97% of cancers that were later found to be aggressive in biopsies.

Another urine-based test, the University of Michigan’s Michigan Prostate Score, has been available since 2013 and has been shown to reduce the number of negative biopsies by 50% while delaying the finding of just 1% of high-risk cancers.

 

What if the biopsy is negative?

The typical 12-core prostate biopsy, which samples only about 1% of the prostate gland, can miss about 25% of cancers. In the past, men with a negative biopsy who still have other signs of prostate cancer, such as a rising PSA, have undergone second, third or fourth biopsies to search for tumors.

A new test called ConfirmMDx, also from MDxHealth, searches biopsied tissue for precancerous changes known as the “field” or “halo,” suggesting a tumor may be lurking nearby. In a 2013 study in the Journal of Urology, ConfirmMDx identified two-thirds of prostate cancers missed on first biopsy, and correctly identified two-thirds of patients who could correctly forgo a repeat biopsy.

 

What about imaging?

Some urologists are using advanced imaging studies known as multiparametric MRIs, or mpMRIs, to guide initial and repeat biopsies. Several recent studies show a technique called fusion biopsy, combining MRI and ultrasound images, results in much higher accuracy for biopsies.

Dr. Mark Scholz at Prostate Oncology Specialists in Marina del Rey, Calif., says an mpMRI can yield much of the same information as a biopsy and far less invasively.

Some urologists are using mpMRI instead of biopsies for patients who opt for active surveillance of low-risk prostate cancers.

Mark Scholz, a prostate oncology specialist in Marina del Rey, Calif., maintains that an mpMRI can yield much of the same information as a biopsy and far less invasively. Low-risk prostate cancers barely register, he says, adding, “When patients find out they have a choice between 12 harpoon sticks to the prostate through the rectum or an MRI, they are on board big time.”

Joel Copeland, 62 years old, has been monitoring his PSA closely for a decade; his two brothers were diagnosed with prostate cancer. He opted for an MRI instead of a biopsy when his PSA bounced up in 2013. “I don’t like needles, but that’s not the point,” Mr. Copeland says. “The point is, biopsies can cause infection and miss cancers.”

Other urologists cite studies showing mpMRIs can miss an many as 16% of significant cancers and suggest patients also get a traditional biopsy. “Just because you have a negative MRI doesn’t mean you don’t have cancer,” Dr. Eggener says.

The biopsy is positive - now what?

Traditionally, urologists have urged men whose biopsies show prostate cancer with a Gleason score of 7 or higher to proceed immediately with surgery or radiation. Increasingly, doctors are counseling those with a Gleason 6 score, the lowest possible, to opt for “active surveillance” of the cancer.

Now, though, even some Gleason 7s are thought to be indolent, while about 20% of Gleason 6s are found to have been aggressive if the prostate was removed.

Dr. Jeremy Lieb, of Pacific Urology, says the new tests are useful in part because they reassure patients with low-risk cancers that it’s OK to watch and wait. 

The new tests aim to provide better predictive information by analyzing the genetic makeup of tissue sampled in a biopsy. Even for patients with low-risk cancers, “it helps to have some validation to tell them, ‘you can just wait and watch it’,” says Jeremy Lieb, Mr. Piazza’s urologist in Walnut Creek, Calif., who has participated in some Prolaris test studies.

Prolaris examines the RNA expression of 46 genes involved in tumor-cell growth and predicts a patient’s likelihood of dying from prostate cancer in the next 10 years. OncotypeDx, by Genomic Health, studies a different set of 17 genes and predicts the patient’s chance of having a “favorable pathology,” or a cancer that won’t metastasize.

The two tests each cost from $3,000 to $4,000. They are covered by Medicare and most insurers for patients with low or very low risk cancers.

ProMark, by MetaMark Genetics, measures protein levels of eight biomarkers in tumor tissue to predict aggressiveness. GenomeDx Biosciences announced in March that its Decipher test, which predicts the risk of cancer recurrence after a prostatectomy, can be used to evaluate cancers in newly diagnosed patients as well.

Dr. Loeb of NYU says the tests are most useful when a patient’s cancer pathology is borderline. “If the patient already has aggressive disease, we don’t need a test to tell us,” she says. “And if it’s very low risk, only a tiny amount of Gleason 6, there’s already good data that shows we can use active surveillance.”

Prostate cancer experts say more tests are needed to spot and derail aggressive prostate cancers that kill about 26,000 Americans a year. “The goal should be that we can see a man’s prostate cancer coming from so far away that it never harms him,” says Jonathan Simons, president of the nonprofit Prostate Cancer Foundation, which helps fund research.

Write to Melinda Beck at HealthJournal@wsj.com

 



READ MORE

6

July 2016

Cancer Risks in Minorities

By: Epoch

When it comes to your risk for cancer, there are certain factors you can control. Eat healthier. Be more active. Quit smoking. However, sometimes, risk Minorities and cancerfactors are beyond your control. If you have a family history of cancer and unfortunately your race can also affect risk. Minority groups in the U.S. continue to have a greater risk for cancer than whites.

The cancer death rate among African American men is 27% higher compared to white men. Researchers have found variants in DNA that are associated with the risk of developing prostate cancer. Nearly all of the variants related to the risk were found most often in black men. However, many times this disparity has to do with poverty, lack of access to detection services and treatment, so these facts don’t have to necessarily remain true.

However, the sad fact is that about one in two black men and one in three black women will be diagnosed with cancer in their lifetimes, according to the American Cancer Society. The most common for black males is prostate cancer. The American Cancer Society estimates that 29,530 cases of prostate cancer will be diagnosed in black men in 2016. This demographic also has the highest death rate.

The best prevention measure is screening and regular checkups with your physician. Cancer risks also are a result of lifestyle choices so using tobacco, being physically inactive or overweight or drinking alcohol in excess contribute to your personal risk. Also, remember that prostate cancer can run in families. One of the best choices you can make for your family is to get regular screenings and make lifestyle decisions for better health.

The good news is that despite the disparity, rates are improving. The death rate for cancers among African Americans has been declining since the 1990s. To learn more about your risk for cancer or to talk to a physician about a concern, give us a call today at 1-877-321-8452.

READ MORE

6

July 2016

5 Facts You Might Not Know About Kidney Cancer

By: Epoch

 

Kidney cancer accounts for about three percent of all cancers in the U.S. While the rate of kidney cancer is increasing, the death rate has been declining since the 1990s. Since March is National Kidney Month, here are five things you might not know about kidney cancer.

1. It’s not unusual for kidney cancer not to have any symptoms especially in the early stages. In fact in many cases, kidney cancer is not diagnosed until it has already spread. Kidney cancer is often detected in its early stage through routine checkups.

2. Kidney cancer occurs about twice more often in men and women, and it’s usually diagnosed between the ages of 50-70. People are rarely diagnosed younger than age 45.

3. If a sibling has kidney cancer, your risk for developing kidney cancer is higher than if your parent has it. Experts think environment just as well as genetics can play a role in your risk.

4. Renal cell cancer is the most common type of kidney cancer. This is when malignant cancer cells form a tumor in the tubules of the kidney. If it’s caught early, the chance of the cancer coming back is very low. However, it is hard to detect in the early stages.

5. A person can live with only part of a working kidney. For many cases, the treatment includes surgery to remove part or the entire affected kidney. When surgery to remove the tumor isn’t possible, arterial embolization may be used to shrink the tumor. Radiation or chemotherapy can also be part of treatment in addition to surgery. Regardless of treatment, people live long and healthy lives with only one kidney.

If you or a loved one has been diagnosed with kidney cancer or if you have a family history of the condition, give us a call today. Our experts can help you develop the best treatment plan for your condition. Call 1-877-321-8452.


 

READ MORE

Swings for Screens

Teach. Test. Treat. The Swings for Screens Foundation provides free patient education and health screenings for men. We want to be at your next event.

Learn More

Kickoff to Men's Health

Epoch Men’s Health observes National Prostate Cancer Awareness Month each September by offering men a free and complete health screening.

More Information